Sasanlimab

Unassigned

New Medicines

Non-muscle invasive bladder cancer (NMIBC) - in combination with BCG

Information

New molecular entity
Pfizer
Pfizer

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Monoclonal antibody that targets and inhibits programmed cell death 1 ligand (PDCD1)
Overall incidence in the UK is 11.4 per 100,000 population. Bladder cancer is the cause over more than 5,000 deaths in the UK each year. At diagnosis, only about 5% of patients have metastatic disease, usually to lymph nodes, lung, liver, bone and central nervous system. Around 30% have involvement of the muscle layer. Around 70% have superficial disease, of which 10% is CIS [1].
Non-muscle invasive bladder cancer (NMIBC) - in combination with BCG
Parenteral